Auriga

Auriga has published a research report on Illumina (NASDAQ: ILMN) commenting on Roche's tender offer to acquire the company for $44.50/share. In the report, Auriga writes, "Roche noted its offer is a 64% premium over ILMN's stock price on December 21, 2011 – one day prior to rumors about a...

Auriga has raised the price target on Apple (NASDAQ: AAPL) from $550 to $650 and maintains its Buy rating.

Auriga has raised the price target on Altera (NASDAQ: ALTR) from $36 to $38 and maintains its Hold rating.

Auriga reiterates its Buy rating on Cisco (NASDAQ: CSCO) and raises its price target up $2 to $24 as the company should benefit from improving product cycles and strength in Enterprise and the public sector. Auriga says, "Our analysis/checks suggest that CSCO is benefiting from a stronger...

Auriga reiterates its Buy rating on Western Digital (NYSE: WDC) and raises its price target to $59, up $5, as the company exceeds estimates and merger catalysts appear to be underestimated. Auriga says, "WD exceeded recently increased estimates, due entirely to higher than expected pricing and...

Auriga reiterates its Buy rating and $110 target price on TransDigm (NYSE: TDG) as the company's acquisition of AmSafe for $750 should boost EPS in 2012 by $0.30. Auriga says, "Friday after the close, TransDigm announced it entered into a definitive agreement to acquire AmSafe Global Holdings, Inc...

Auriga maintains its Buy rating and $56 target price on Crane (NYSE: CR) as it expects the company to have a strong finish in 2011 and a strong outlook for 2012. Auriga says, "Today after the close, Crane Co. is expected to report fourth-quarter results. We expect a solid finish to the year...

Auriga reiterates its Hold rating on Under Armour (NYSE: UA) and lowers its estimates down $12 to $70 to reflect slashed estimated due to an unseasonably warm winter. Auriga says, "We are lowering our Q4 EPS estimate to $0.58 from $0.61 ahead of UA's Q4 earnings report on January 26. We believe...

According to Auriga, Xilinix (NASDAQ: XLNX) price target is raised to $40. Auriga said that it maintains its Buy rating for Xilinx (XLNX) and increase its price target to $40 from $36 as the company's print/guide was significantly better than expectations. “We still remain cautious on overall...

Auriga has raised the price target on Xilinx (NASDAQ: XLNX) from $36 to $40 and maintains its Buy rating.

Auriga raises its rating on 3SBio (NASDAQ: SSRX) to Buy from Hold on attractive valuation, and reiterates its $13 target price. Auriga notes, "Fundamental story has not changed. 3Sbio remains a top-tier biotech company operating in China. We continue to see strong demand growth in the company's...

Auriga downgrades IST Pharmaceuticals (NASDAQ: ISTA) to a Hold rating and a $9 PT on an increased buyout from Valeant. Auriga says, "Valeant increased the offer from $6.50 to $7.50-$8.50. Our view for the offer is that it is getting very interesting. The high end of the Valeant offer and low end...

According to a research report published by Auriga, Thoratec Corporation's (NASDAQ: THOR) HeartMate II is experiencing an increased rate of thrombosis based on recent checks on the VAD space. Auriga commented that, “The increased thrombosis rate is surprising given HM II's long history, low...

Auriga has downgraded ISTA Pharmaceuticals (NASDAQ: ISTA) from Buy to Hold and has a $9 price target.

Auriga has upgraded 3SBio (NASDAQ: SSRX) from Hold to Buy and has a $13 price target.